Przejdź do zawartości
Merck
Wszystkie zdjęcia(1)

Key Documents

View All Documentation

1013002

USP

Allopurinol

United States Pharmacopeia (USP) Reference Standard

Synonim(y):

1H-Pyrazolo(3,4-d)pyrimidin-4-ol, 4-Hydroxypyrazolo(3,4-d)pyrimidine, 4-Hydroxypyrazolo[3,4-d]pyrimidine, HPP

Zaloguj sięWyświetlanie cen organizacyjnych i kontraktowych
Wszystkie zdjęcia(1)

About This Item

Wzór empiryczny (zapis Hilla):
C5H4N4O
Numer CAS:
315-30-0
Masa cząsteczkowa:
136.11
Numer MDL:
MFCD00599413
Kod UNSPSC:
41116107
Identyfikator substancji w PubChem:
329748958
NACRES:
NA.24

klasa czystości

pharmaceutical primary standard

rodzina API

allopurinol

producent / nazwa handlowa

USP

mp

>300 °C (lit.)

Zastosowanie

pharmaceutical (small molecule)

format

neat

temp. przechowywania

15-25°C

ciąg SMILES

O=C1NC=Nc2[nH]ncc12

InChI

1S/C5H4N4O/c10-5-3-1-8-9-4(3)6-2-7-5/h1-2H,(H2,6,7,8,9,10)

Klucz InChI

OFCNXPDARWKPPY-UHFFFAOYSA-N

informacje o genach

human ... XDH(7498)

Szukasz podobnych produktów? Odwiedź Przewodnik dotyczący porównywania produktów

Powiązane kategorie

Opis ogólny

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Zastosowanie

Allopurinol USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Allopurinol Compounded Oral Suspension
  • Allopurinol Tablets

Działania biochem./fizjol.

Inhibitor of xanthine oxidase and de novo pyrimidine biosynthesis. A classical agent in treatment of hyperuricemia and gout.

Komentarz do analizy

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Inne uwagi

Sales restrictions may apply.
This page may contain text that has been machine translated.

produkt powiązany

Numer produktu
Opis
Cennik

1013035

Allopurinol Related Compound C, United States Pharmacopeia (USP) Reference Standard

A0350040

Allopurinol impurity D, European Pharmacopoeia (EP) Reference Standard

A0350010

Allopurinol impurity A, European Pharmacopoeia (EP) Reference Standard

A0350000

Allopurinol, European Pharmacopoeia (EP) Reference Standard

A0350020

Allopurinol impurity B, European Pharmacopoeia (EP) Reference Standard

A0350030

Allopurinol impurity C, European Pharmacopoeia (EP) Reference Standard

A0350050

Allopurinol impurity E, European Pharmacopoeia (EP) Reference Standard

1013046

Allopurinol Related Compound D, United States Pharmacopeia (USP) Reference Standard

1013013

Allopurinol Related Compound B, United States Pharmacopeia (USP) Reference Standard

1013024

Allopurinol Related Compound A, United States Pharmacopeia (USP) Reference Standard

1013068

Allopurinol Related Compound E, United States Pharmacopeia (USP) Reference Standard

1013079

Allopurinol Related Compound F, United States Pharmacopeia (USP) Reference Standard

BP870

Allopurinol, British Pharmacopoeia (BP) Reference Standard

PHR2005

Allopurinol Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2006

Allopurinol Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2007

Allopurinol Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2008

Allopurinol Related Compound D, Pharmaceutical Secondary Standard; Certified Reference Material

PHR2009

Allopurinol Related Compound E, Pharmaceutical Secondary Standard; Certified Reference Material

BP832

Allopurinol impurity B, British Pharmacopoeia (BP) Reference Standard

BP844

Allopurinol impurity D, British Pharmacopoeia (BP) Reference Standard

BP845

Allopurinol impurity E, British Pharmacopoeia (BP) Reference Standard

BP843

Allopurinol impurity C, British Pharmacopoeia (BP) Reference Standard

Piktogramy

Skull and crossbones
GHS06

Hasło ostrzegawcze

Danger

Zwroty wskazujące rodzaj zagrożenia

H301,H317

Zwroty wskazujące środki ostrożności

P261 - P264 - P270 - P280 - P301 + P310 - P302 + P352

Klasyfikacja zagrożeń

Acute Tox. 3 Oral - Skin Sens. 1

Kod klasy składowania

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Klasa zagrożenia wodnego (WGK)

WGK 2

Temperatura zapłonu (°F)

Not applicable

Temperatura zapłonu (°C)

Not applicable

Certyfikaty analizy (CoA)

Poszukaj Certyfikaty analizy (CoA), wpisując numer partii/serii produktów. Numery serii i partii można znaleźć na etykiecie produktu po słowach „seria” lub „partia”.

Masz już ten produkt?

Dokumenty związane z niedawno zakupionymi produktami zostały zamieszczone w Bibliotece dokumentów.

Odwiedź Bibliotekę dokumentów

Jennifer J DuPont et al.
American journal of physiology. Renal physiology, 306(12), F1499-F1506 (2014-04-25)
Oxidative stress promotes vascular dysfunction in chronic kidney disease (CKD). We utilized the cutaneous circulation to test the hypothesis that reactive oxygen species derived from NADPH oxidase and xanthine oxidase impair nitric oxide (NO)-dependent cutaneous vasodilation in CKD. Twenty subjects
Dino Premilovac et al.
Diabetologia, 57(12), 2586-2595 (2014-09-13)
High sodium (HS) effects on hypertension are well established. Recent evidence implicates a relationship between HS intake and insulin resistance, even in the absence of hypertension. The aim of the current study was to determine whether loss of the vascular
C C Wen et al.
Clinical pharmacology and therapeutics, 97(5), 518-525 (2015-02-14)
The first-line treatment of hyperuricemia, which causes gout, is allopurinol. The allopurinol response is highly variable, with many users failing to achieve target serum uric acid (SUA) levels. No genome-wide association study (GWAS) has examined the genetic factors affecting allopurinol
Timothy Pearson et al.
PloS one, 9(5), e96378-e96378 (2014-05-31)
Skeletal muscle generation of reactive oxygen species (ROS) is increased following contractile activity and these species interact with multiple signaling pathways to mediate adaptations to contractions. The sources and time course of the increase in ROS during contractions remain undefined.
Lisa K Stamp et al.
Rheumatology (Oxford, England), 53(11), 1958-1965 (2014-06-06)
The aims of this study were to establish whether, in patients with gout, MPO is released from neutrophils and urate is oxidized to allantoin and if these effects are attenuated by allopurinol. MPO, urate, allantoin and oxypurinol were measured in
Wyświetl wszystkie powiązane dokumenty

Nasz zespół naukowców ma doświadczenie we wszystkich obszarach badań, w tym w naukach przyrodniczych, materiałoznawstwie, syntezie chemicznej, chromatografii, analityce i wielu innych dziedzinach.

Skontaktuj się z zespołem ds. pomocy technicznej